
- /
- Supported exchanges
- / US
- / KPRX.NASDAQ
Kiora Pharmaceuticals Inc (KPRX NASDAQ) stock market data APIs
Kiora Pharmaceuticals Inc Financial Data Overview
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Kiora Pharmaceuticals Inc data using free add-ons & libraries
Get Kiora Pharmaceuticals Inc Fundamental Data
Kiora Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 20 000
- EBITDA: -9 669 589
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.77
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kiora Pharmaceuticals Inc News

Top Midday Gainers
ReShape Lifesciences (RSLS) said Tuesday that its Quality Management System and entire commercial po PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...


Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
It has been a busy week for the biotech sector as quite a few big companies came out with fourth-quarter results. Other pipeline and regulatory updates were also in focus. Recap of the Week’s Most ...

Kiora’s stock rallies as eye drop treatment moves into mid-stage clinical trial
MARKET PULSE Shares of Kiora Pharmaceuticals Inc. (KPRX) soared about 57% in premarket trading on Tuesday after the company said it will begin a Phase 2 clinical trial for its experimental eye drops as a treatment for ocular rheumatoid arthritis. Continue reading

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It’s time to kick off the day with a dive into the biggest pre-market stock movers for Tuesday! Wall Street in the early morning light representing Pre-Market Stock Movers. So...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.